Andrew R. Allen, See Remarks at Clovis Oncology, Inc. (CLVS), sold 49,176 shares at $65.88 ($3.2M) on 2015-01-16, disclosed to the SEC on 2015-01-20.
Scheduled sale ($3.2M) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CLVS | SELL | 2015-01-21 | $5.3M | — | Filing → |
| CLVS | SELL | 2013-06-07 | $1.5M | — | Filing → |
| CLVS | BUY | 2011-11-21 | $50K | — | Filing → |